ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,048.42
      -0.46%
      US Tech 100
      17,217.60
      0.92%
      Dow Jones
      38,085.80
      -0.98%
      Brent Oil
      88.095
      1.00%
      Bitcoin
      64,924.57
      1.00%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Ultragenyx Pharmaceutical Inc (RARE)

      7. Ultragenyx Pharmaceutical Inc (RARE) News

      RARE Ultragenyx Pharmaceutical Inc

      43.85
      -0.43 (-0.97%)
      After Hours
      Last Updated: 16:07:24
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      Ultragenyx Pharmaceutical Inc RARE NASDAQ Common Stock
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      -0.43 -0.97% 43.85 16:07:24
      Open Price Low Price High Price Close Price Prev Close
      43.41 42.73 43.995 43.85 44.28
      more quote information »

      Recent News

      Date Time Source Heading
      4/25/20248:52IHNWFeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
      4/25/202416:30GLOBEUltragenyx to Host Conference Call for First Quarter 2024..
      4/19/202416:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
      4/15/202407:00GLOBEUltragenyx Announces Positive Interim Phase 1/2 Data in..
      4/12/202416:22GLOBEUltragenyx Announces Update to Conference Call Timing to..
      4/12/202408:00GLOBEUltragenyx Announces Upcoming Data Presentations at American..
      3/22/202416:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
      3/05/202420:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/05/202420:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/05/202420:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/05/202420:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/05/202420:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/05/202420:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      3/05/202420:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      2/27/202416:30GLOBEUltragenyx to Participate at Investor Conferences in March
      2/23/202416:05GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
      2/21/202417:03EDGAR2Form S-3ASR - Automatic shelf registration statement of..
      2/15/202416:04EDGAR2Form 8-K - Current report
      2/15/202416:01GLOBEUltragenyx Reports Fourth Quarter and Full Year 2023..
      2/08/202416:00GLOBEUltragenyx to Host Conference Call for Fourth Quarter and..
      2/06/202408:00GLOBEUltragenyx Announces Data Demonstrating Treatment with UX111..
      2/05/202416:05GLOBEUltragenyx Receives PRIME Designation from European..
      1/25/202416:05GLOBEUltragenyx Announces Completion of Dosing Across Stage 1..
      1/19/202416:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
      1/08/202407:00GLOBEMereo BioPharma Provides Update on Pipeline Progress and..
      1/08/202406:03EDGAR2Form 8-K - Current report
      1/07/202411:00GLOBEUltragenyx Reports Preliminary 2023 Revenue; Guidance for..
      1/04/202408:00GLOBEUltragenyx Receives Positive Recommendation from NICE in the..
      1/03/202408:00GLOBEUltragenyx Announces Completion of Enrollment in Global..
      1/02/202416:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
      1/02/202416:05GLOBEUltragenyx to Present at the 42nd Annual J.P. Morgan..
      12/21/202317:45DJNUltragenyx to Pay $6 Million to Settle Alleged False..
      12/21/202316:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
      12/21/202316:02EDGAR2Form 8-K - Current report
      12/18/202308:00GLOBEUltragenyx Receives European Commission Decision for..
      11/20/202316:30GLOBEUltragenyx to Participate at Investor Conferences in..
      11/17/202316:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
      11/07/202317:00GLOBEUltragenyx to Participate in the Jefferies London Healthcare..
      11/02/202316:17EDGAR2Form 8-K - Current report
      11/02/202316:05GLOBEUltragenyx Reports Third Quarter 2023 Financial Results and..
      10/26/202316:05GLOBEUltragenyx to Host Conference Call for Third Quarter 2023..
      10/23/202316:01GLOBEUltragenyx Announces Closing of Public Offering of Common..
      10/23/202306:31EDGAR2Form 8-K - Current report
      10/20/202316:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
      10/20/202306:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      10/18/202321:16GLOBEUltragenyx Announces Pricing of Public Offering of Common..
      10/17/202316:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      10/17/202316:02GLOBEUltragenyx Announces Proposed Public Offering of Common..
      10/16/202308:05EDGAR2Form 8-K - Current report
      10/16/202308:00GLOBEUltragenyx Announces Program and Pipeline Updates at Analyst..
      10/14/202316:30GLOBEUltragenyx and Mereo BioPharma Announce Interim Phase 2 Data..

      Your Recent History

      NASDAQ
      RARE
      Ultragenyx Pharmaceutical
      Delayed Upgrade Clock